Zobrazeno 1 - 10
of 181
pro vyhledávání: '"SRC inhibitor"'
Autor:
John C. Dawson, Alison Munro, Kenneth Macleod, Morwenna Muir, Paul Timpson, Robert J. Williams, Margaret Frame, Valerie G. Brunton, Neil O. Carragher
Publikováno v:
Molecular Oncology, Vol 16, Iss 5, Pp 1072-1090 (2022)
A more comprehensive understanding of how cells respond to drug intervention, the likely immediate signalling responses and how resistance may develop within different microenvironments will help inform treatment regimes. The nonreceptor tyrosine kin
Externí odkaz:
https://doaj.org/article/fab8f61f00ef4132b7b597f9dca6a022
Autor:
Marion Vanneste, Charlotte R. Feddersen, Afshin Varzavand, Elliot Y. Zhu, Tyler Foley, Lei Zhao, Kathleen H. Holt, Mohammed Milhem, Robert Piper, Christopher S. Stipp, Adam J. Dupuy, Michael D. Henry
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Patients with malignant melanoma have a 5-year survival rate of only 15–20% once the tumor has metastasized to distant tissues. While MAP kinase pathway inhibitors (MAPKi) are initially effective for the majority of patients with melanoma harboring
Externí odkaz:
https://doaj.org/article/95a586feb3bf41228e4c027d0dc87c64
Autor:
Enrico Rango, Fabio Pastorino, Chiara Brignole, Arianna Mancini, Federica Poggialini, Salvatore Di Maria, Claudio Zamperini, Giulia Iovenitti, Anna Lucia Fallacara, Samantha Sabetta, Letizia Clementi, Massimo Valoti, Silvia Schenone, Adriano Angelucci, Mirco Ponzoni, Elena Dreassi, Maurizio Botta
Publikováno v:
Biomedicines, Vol 10, Iss 3, p 659 (2022)
Si306, a pyrazolo[3,4-d]pyrimidine derivative recently identified as promising anticancer agent, has shown favorable in vitro and in vivo activity profile against neuroblastoma (NB) models by acting as a competitive inhibitor of c-Src tyrosine kinase
Externí odkaz:
https://doaj.org/article/76fcd042be33447e9734d22a84d6e765
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Man Yuan, Lin-feng Xu, Juan Zhang, Si-yuan Kong, Man Wu, Yuan-zhi Lao, Hua Zhou, Li Zhang, Hongxi Xu
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Non-small-cell lung cancer (NSCLC) is the predominant form of lung cancer, and it is regulated by a complex signal transduction network. Single-agent targeted therapy often results in acquired resistance, which leads to treatment failure. In this stu
Externí odkaz:
https://doaj.org/article/b71d4ded94014ca59853aa2a240ccdf6
Publikováno v:
Respiratory Research, Vol 15, Iss 1, Pp 1-9 (2014)
Abstract Background Ventilator-induced lung injury (VILI) is characterized by increased alveolar permeability, pulmonary edema. The tyrosine kinase, c-Src, is involved in VILI but its role has not been fully elucidated. This study examined the relati
Externí odkaz:
https://doaj.org/article/2f68e96ad2744929ae117ee79f3bb0b2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Richard Marais, Grazia Saturno, Robert McLeary, Cyril Fisher, Udai Banerji, Alfonso Zambon, Lawrence Davies, Rebecca Lee, J.M.G. Larkin, Natasha Preece, Emma Dean, Paul Lorigan, Dan Niculescu-Duvaz, Matthew G Krebs, Amaya Viros, Nathalie Dhomen, Malin Pedersen, L. Johnson, Filipa Lopes, Caroline J. Springer, D. Holovanchuk, M. E. Gore, Ion Niculescu-Duvaz
Publikováno v:
Annals of Oncology
Saturno, G, Lopes, F, Niculescu-Duvaz, I, Niculescu-Duvaz, D, Zambon, A, Davies, L, Johnson, L, Preece, N, Lee, R, Viros Usandizaga, A, Holovanchuk, D, Pedersen, M, Mcleary, R, Lorigan, P, Dhomen, N, Fisher, C, Banerji, U, Dean, E, Krebs, M, Gore, M, Larkin, J, Marais, R & Springer, C 2021, ' The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers ', Annals of Oncology, vol. 32, no. 2, pp. 269-278 . https://doi.org/10.1016/j.annonc.2020.10.483
Saturno, G, Lopes, F, Niculescu-Duvaz, I, Niculescu-Duvaz, D, Zambon, A, Davies, L, Johnson, L, Preece, N, Lee, R, Viros Usandizaga, A, Holovanchuk, D, Pedersen, M, Mcleary, R, Lorigan, P, Dhomen, N, Fisher, C, Banerji, U, Dean, E, Krebs, M, Gore, M, Larkin, J, Marais, R & Springer, C 2021, ' The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers ', Annals of Oncology, vol. 32, no. 2, pp. 269-278 . https://doi.org/10.1016/j.annonc.2020.10.483
Background KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting G12CKRAS specifically, but therapeutic options for other mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9dd4c81e95c2a5d81da34368a411222
http://europepmc.org/articles/PMC7839839
http://europepmc.org/articles/PMC7839839
Publikováno v:
The FASEB Journal. 34:13586-13596
Endothelial microparticles (EMPs) are involved in various cardiovascular pathologies and play remarkable roles in communication between endothelial cells (ECs), which are constantly exposed to mechanical cyclic stretch (CS) following blood pressure.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34d38948b560b528eb7ecbb5a8da4cfe
https://doi.org/10.1096/fj.202000581r
https://doi.org/10.1096/fj.202000581r
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.